Prognostic impact of the combination of erythropoiesis-stimulating agents to cancer treatment: literature review.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

PubMedID: 23775155

Boulaamane L, Goncalves A, Boutayeb S, Viens P, M'rabti H, Bertucci F, Errihani H. Prognostic impact of the combination of erythropoiesis-stimulating agents to cancer treatment: literature review. Support Care Cancer. 2013;21(8):2359-69.
Cancer patients commonly develop anaemia. Erythropoiesis-stimulating agents (ESAs) are frequently used in cancer treatment. Numerous controlled studies indicate that ESAs can raise haemoglobin levels, reduce transfusion requirements and improve quality of life in anaemic cancer patients receiving chemotherapy. They were previously used to enhance response to radiation therapy, via increasing tumour cell oxygenation. Since the 2002 guideline, there has been increasing attention to the safety of ESA treatment in patients with cancer. Two placebo-controlled phase III randomised clinical trials published in 2003 showed evidence of harmful effects of ESAs on survival and/or tumour outcomes. Subsequently, recent trials and several large meta-analyses have confirmed negative impact on survival and/or disease progression. To comprehensively examine whether ESA use affects safety outcomes in cancer patients in different settings (chemotherapy, radiotherapy and targeted therapies), we conducted a literature review of all clinical trials, small and large meta-analyses from 1990 to 2012.